期刊文献+

P-gp、MMP-2、C-erbB-2在乳腺癌原发灶和转移淋巴结中的表达对比研究 被引量:3

Expression and clinical significance of P-gp,MMP-2 and c-erbB-2 in infiltrating ductal breast cancer and metastatic axillary lymph nodes
原文传递
导出
摘要 目的:探讨乳腺癌侵袭转移和多药耐药之间的关系,为治疗方案的个体化提供依据。方法:采用免疫组化方法检测46例乳腺浸润性导管癌患者乳腺原发灶及相应腋淋巴结转移灶中P-gp、MMP-2、c-erbB-2的表达,结合临床表现、病理学指标,分析其相关性。结果:46例原发灶P-gp阳性表达35例(76.1%),MMP-2阳性表达25例(54.3%),c-erbB-2高表达18例(39.1%);相应腋淋巴结转移灶P-gp阳性表达28例(60.9%),MMP-2阳性表达16例(34.8%),c-erbB-2高表达16例(34.8%);P-gp、MMP-2蛋白表达水平与肿块大小、淋巴结转移数目均呈正相关(P<0.05),c-erbB-2蛋白表达水平与腋窝淋巴结转移数量呈正相关,与ER、PR表达呈负相关,P-gp阳性表达与MMP-2和c-erbB-2的表达呈正相关(P<0.05)。结论:肿瘤原发灶与转移灶存在异质性,P-gp、MMP-2、c-erbB-2的表达与乳腺癌的多药耐药和侵袭转移有关,检测上述基因在原发灶与转移灶的表达,为乳腺癌选择个体化的化疗、内分泌治疗及分子靶向治疗提供了分子生物学依据。 Objective: To observe the expression of P-gp,MMP-2 and c-erbB-2 in primary tumor and their metastatic axillary lymph nodes and study the relationship with clinicopathology characteristics and also the correlation between P-gp,MMP-2 and c-erbB-2.Methods: Immunohistochemical technique was performed to detect the expression of P-gp,MMP-2 and c-erbB-2 in 46 cases of infiltrating ductal breast cancer with primary tumor and their metastatic axillary lymph nodes without undergoing neo-adjuvent therapy.Their clinical and pathological indices and follow up data were analyzed.Results: The positive rate of P-gp in primary tumor was 76.1%(35/46)and in metastatic axillary lymph nodes was 60.9%(28/46),the expression of Pg-p was significantly correlated with the tumor size and lymph node metastasis(P 0.05).The positive rate of MMP-2 in primary tumor was 54.3%(25/46)and in metastatic axillary lymph nodes was 34.8%(16/46),the expression of MMP-2 was significantly correlated with the tumor size and lymph node metastasis(P 0.05).The overexpression rate of c-erbB-2 in primary tumor was 39.1%(18/46) and in metastatic axillary lymph nodes was 34.8%(16/46),The expression of c-erbB-2 was significantly correlated with the expression of ER and PR and lymph node metastasis(P 0.05),but not with the age and the tumor size(P 0.05).11,12 and 13 of 46 cases showed a discordance of MMP-2,P-gp and c-erbB-2 status between primary carcinoma and synchronous lymph node metastases.Conclusions: P-gp,MMP-2 and c-erbB-2 was correlated with the multidrug resistance and metastatic behavior in breast cancer,to detect the expression of the three genes may be helpful in choosing the treatment of breast cancer with chemotherapy endocrine therapy and gene therapy.
出处 《现代生物医学进展》 CAS 2011年第1期94-97,148,共5页 Progress in Modern Biomedicine
关键词 乳腺肿瘤 多药耐药 肿瘤转移 肿瘤异质性 P-GP MMP-2 C-ERBB-2 breast neoplasms multidrug resistance neoplasm metastasis tumor heterogeneity P-gp MMP-2 c-erbB-2
  • 相关文献

参考文献9

  • 1李占文,杨华锋,胡云锵,李振平,刘纯,范风风.112例乳腺癌P-gp表达与临床病理相关因素分析[J].实用肿瘤学杂志,2006,20(5):419-420. 被引量:2
  • 2Jukkola A, Bloigu R, Soini Y, et al.C-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease [J]. Eur J Cancer, 2001,37(3):347-354.
  • 3Hanemaaijer R, Verheijen JH, Magcirc TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors[J]. Int J Cancer, 2000,86(2):204-207.
  • 4De Larco JE, Wuertz BR, Manivel JC, et al. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents[J]. Cancer Res, 2001, 61(7) : 2857-2861.
  • 5张飞,史玉荣,张霖,张斌,魏熙胤,杨毅,席广民,牛瑞芳.乳腺癌多药耐药细胞MCF-7/ADR中Twist的表达与EMT现象的实验研究[J].中国肿瘤临床,2007,34(7):361-365. 被引量:14
  • 6Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials[J].BMC Cancer, 2007,7:153-163.
  • 7张玉宝,马春雷,张国强,张岂凡.乳腺癌原发灶和淋巴结转移灶MDR-1基因表达及临床分析[J].中国肿瘤临床,2004,31(21):1221-1224. 被引量:4
  • 8Hao X, Sun B, Hu L, et al. Distinctive gene and protein expression between primary breast cancers and their lymph node metastases revealed by combined eDNA rnicroarray and tissue microarray. Cancer, 2004, 100(6): 1110-1122.
  • 9Santinelli A, Pisa E, Stramazzotti D, et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer, 2008,122(5):999-1004.

二级参考文献29

共引文献16

同被引文献45

  • 1张玉宝,马春雷,张国强,张岂凡.乳腺癌原发灶和淋巴结转移灶MDR-1基因表达及临床分析[J].中国肿瘤临床,2004,31(21):1221-1224. 被引量:4
  • 2张飞,史玉荣,张霖,张斌,魏熙胤,杨毅,席广民,牛瑞芳.乳腺癌多药耐药细胞MCF-7/ADR中Twist的表达与EMT现象的实验研究[J].中国肿瘤临床,2007,34(7):361-365. 被引量:14
  • 3张晓,徐文华,葛银林,侯琳,李泉.VEGF基因特异性siRNA转染后对人乳腺癌细胞增殖和凋亡的影响[J].细胞与分子免疫学杂志,2007,23(1):14-17. 被引量:7
  • 4Ferrara N,Gerber HP,Lecouter J.The biology of VEGF and its recep-tors[J].Nat Med,2003,9:669-676.
  • 5Matsumura S,Oue N,Mitani Y,et al.DNA demethylation of Vascularendothelial growth factor is associated with gene expression and itspossible involvement of lymphangiogenesis in gastric cancer[J].Inter-national Journal of Cancer,2007,120(8):1689-1695.
  • 6Gerber HP,Ferrara N.The role of VEGF in normal and neoplastichematopoiesis[J].J M Med,2003,81(1):20-31.
  • 7Howard EIVI,Lau SK,Lyles RH,et a1.Corelation and expression ofp53,HER-2,vascular endothelial growth factor(VEGF)and E-cad-herin in a high-risk breast-cancer population[J].Int J Clin Oncol,2004,9(1):154-159.
  • 8Guo B,Zhang Y,Luo G,et al.Lentivirus-Mediated Small InterferingRNA Targeting VEGF Inhibited Tumor Lymphangiogenesis andGrowth in Breast Carcinoma[J].Anatomical Record,2009,292(5):633-639.
  • 9Pimia F, Breuleux M, Schneider E,et al. Uncertain identity of doxoru-bicin-resistant MCF-7 cell lines expressing mutated p53 [J]. J NatlCancer Inst, 2000, 92(18):1535-1536.
  • 10Mehta K, Devarajan E, Chen J, et al. Multidrug-resistant MCF-7 cells:an identity crisis.[J]. J Natl Cancer Inst, 2002, 94(21):1652-1654.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部